Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goserelin implant - AMW/Alvogen

Next Previous
Search
Drug Profile

Goserelin implant - AMW/Alvogen

Alternative Names: Reseligo

Latest Information Update: 30 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AMW GmbH
  • Developer Alvogen; AMW GmbH
  • Class Antineoplastics; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Prostate cancer; Uterine diseases; Uterine leiomyoma

Most Recent Events

  • 10 Mar 2021 Phase III trial for Prostate cancer is still ongoing in Germany (EudraCT2010-018735-18)
  • 10 Mar 2021 Phase-III clinical trials in Prostate cancer in Germany (SC)
  • 22 Jan 2019 Goserelin implant is not yet available for Breast cancer, Endometriosis, Female infertility, Prostate cancer, Uterine diseases and Uterine leiomyoma in Portugal, Slovakia, Slovenia and Czech Republic

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top